Background: The Common Toxicity Criteria of the National Cancer Institute evaluates diarrhea as an adverse event of chemotherapy administration. Acute graft versus host disease (aGVHD) causes diarrhea in allogeneic hematopoietic stem cell transplant patients. Guidelines for treating grade 3 and 4 chemotherapy induced diarrhea (CID) include octreotide acetate, a somatostatin analogue. These recommendations are based on adult octreotide trials. Data on octreotide use for treatment of CID in pediatric oncology patients are limited. This study evaluated the efficacy and safety of octreotide in the treatment of CID or aGVHD induced diarrhea in pediatric patients.
Methods: This is a retrospective review of 34 patients of average age 6 years who received octreotide between 1994 and 2008 for treatment of CID or aGVHD induced diarrhea.
Results: Thirty-eight courses of intravenous octreotide were administered. A complete response was achieved during 25/27 (92%) CID and 5/11 (45%) aGVHD induced diarrhea courses. A partial response was achieved during 4/38 courses, all in the aGVHD induced diarrhea group. No response was observed for 3 of the aGVHD induced diarrhea courses and 1 for the CID course. Octreotide was initiated at 2 mcg/kg/day and increased to a maximum of 9 mcg/kg/day. The mean total duration of treatment was 9 days. Common adverse effects observed were hyperglycemia, hyberbilirubinemia, nausea/vomiting, and abdominal cramping.
Conclusion: In pediatric patients, octreotide exhibits 92% efficacy in treating CID and 45% efficacy in aGVHD induced diarrhea. Further studies to better characterize the starting dose and dose escalation algorithm for treating CID in children are required.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pbc.22838 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protective effect of low-dose lactulose in dextran sulfate sodium induced ulcerative colitis model of rats.
Sci Rep
January 2025
Department of Gastroenterology, The First Affiliated Hospital of Xinjiang Medical University, No.137 LiYuShan Road Xinjiang Province, Urumqi, 830000, China.
Although low-dose lactulose has shown a good theoretical foundation for the treatment of ulcerative colitis (UC) in previous studies, the exact effects and mechanism remain unclear. The rats were randomly distributed into 5 groups, i.e.
View Article and Find Full Text PDFLentinan's effect on gut microbiota and inflammatory cytokines in 5-FU-induced mucositis mice.
AMB Express
January 2025
Department of Biotechnology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, China.
Chemotherapeutic therapies for cancer are frequently associated with cytotoxic side effects that can be harmful to human health, including the development of intestinal mucositis (IM). It mostly affects the gastrointestinal tract, causing ulceration, inflammation, and the formation of lesions in the colon. Surprisingly, despite the frequency of IM, therapeutic choices remain restricted.
View Article and Find Full Text PDFBreast milk delivery of an engineered dimeric IgA protects neonates against rotavirus.
Mucosal Immunol
January 2025
Weill Cornell Medicine Department of Pediatrics, Division of Infectious Disease, New York, NY, USA. Electronic address:
Dimeric IgA (dIgA) is the dominant antibody in many mucosal tissues. It is actively transported onto mucosal surfaces as secretory IgA (sIgA) which plays an integral role in protection against enteric pathogens, particularly in young children. Therapeutic strategies that deliver engineered, potently neutralizing antibodies directly into the infant intestine through breast milk could provide enhanced antimicrobial protection for neonates.
View Article and Find Full Text PDFA novel neutralizing antibody recognizing a conserved conformational epitope in PDCoV S1 protein and its therapeutic efficacy in piglets.
J Virol
January 2025
Research Center for Swine Diseases, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, China.
Unlabelled: Porcine deltacoronavirus (PDCoV) is an enteric pathogen that burdens the global pig industry and is a public health concern. The development of effective antiviral therapies is necessary for the prevention and control of PDCoV, yet to date, there are few studies on the therapeutic potential of PDCoV-neutralizing antibodies. Here, we investigate the therapeutic potential of a novel monoclonal antibody (mAb 4A6) which targets the PDCoV S1 protein and effectively neutralizes PDCoV, both pre- and post-attachment on cells, with IC50 values of 0.
View Article and Find Full Text PDFClinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease.
Eur J Med Res
January 2025
Department of Clinical Pharmacy, Xiangtan Central Hospital (The affiliated hospital of Hunan university), 120 Heping Road, Yuhu District, Xiangtan, 411100, Hunan, China.
Background: Inflammatory bowel disease (IBD) is a rare adverse effect linked to secukinumab, with limited clinical data available. This study aimed to analyze the clinical features of secukinumab-induced IBD and to offer recommendations for the careful administration of secukinumab.
Methods: We conducted a retrospective analysis by gathering case reports and case series of secukinumab-induced IBD through a database search, with data collected until September 30, 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!